As per reports, Johnson & Johnson (JNJ) is looking forward to filing for approval of 14 new drugs by 2025, projecting average peak sales of $4 billion a year for each. The global head of research for J&J’s Janssen pharmaceutical unit, Mathai Mammen is reportedly confident about its top upcoming assets, a drug combination for non-small cell lung cancer, an anticoagulant in development with partner Bristol Myers Squibb, and a vaccine for the respiratory syncytial virus.
J&J developed one of the three COVID-19 vaccines authorized in the United States. Mammen informed that J&J still expects to develop more vaccines using the same adenovirus vector technology.
Dow 30 component Johnson & Johnson (JNJ) is a worldwide healthcare-focused company that embraces research and science so that it can provide customers with innovative ideas, products, and services. To learn more about Johnson & Johnson (JNJ) and to continue to track its progress visit the Vista Partners Johnson & Johnson Coverage Page.
If you liked this story please consider, visiting the Atossa Therapeutics (ATOS) dedicated page at Vista Partners to learn about the Seattle-based biotech firm’s work towards finding therapeutic treatments for Breast Cancer and the Coronavirus.
Vista Partners LLC (”Vista”) is a California Registered Investment Advisor based in San Francisco. Vista delivers timely and relevant insights via the website: www.vistapglobal.com with daily stories, weekly market updates, monthly macroeconomic newsletters, podcasts, & Vista’s proprietary equity and market research to help you stay informed and stay competitive. Vista’s mission is to invest partner capital while arming investors with a comprehensive global financial perspective across all market sectors. Vista also seeks to provide select issuers with actionable advice regarding fundamental development, corporate governance, and capital market directives.
Stay Informed! Stay Competitive! Please join us at Vista Partners, receive our FREE email updates throughout the week, and view our exclusive content and research.
